孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的疗效

目的 探讨孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的临床疗效。方法 选择2017年2月~2018年5月我院收治的咳嗽变异性哮喘患儿90例，按照随机数字表法分为研究组和对照组，各45例。对照组给予布地奈德治疗，研究组在对照组基础上加用孟鲁司特钠治疗，比较两组第1秒用力呼气量（FEV1）、用力肺活量（FVC）、FEV1/FVC水平和临床疗效。结果 治疗后，研究组FEV1、FVC及FEV1/FVC水平高于对照组（3.34±1.01）L vs（2.17±0.62）L、（4.23±1.31）L vs（3.19±1.05）L、（78.96±3.25）% vs（66.35±4.79）%]，差异有统计学意义（P＜0.05）。研究组总有效率为91.11%，高于对照组的80.00%，差异有统计学意义（P＜0.05）。结论 孟鲁司特钠联合布地奈德治疗咳嗽变异性哮喘效果明显，促进相关症状消退，改善肺功能，快速稳定病情，为预后提供保障。

Efficacy of Montelukast Sodium Combined with Budesonide in the Treatment of Cough Variant Asthma in Children

Abstract:Objective To investigate the clinical efficacy of montelukast sodium combined with budesonide in the treatment of cough variant asthma in children. Methods 90 children with cough variant asthma admitted to our hospital from February 2017 to May 2018 were enrolled in the study group and the control group, 45 cases each according to the random number table method. The control group was treated with budesonide. The study group was treated with montelukast sodium on the basis of the control group. The forced expiratory volume (FEV1), forced vital capacity (FVC), FEV1/FVC levels, and clinical efficacy were compared between the two groups. Results After treatment, the levels of FEV1, FVC and FEV1/FVC in the study group were higher than those in the control group (3.34±1.01)L vs(2.17±0.62)L, (4.23±1.31)L vs(3.19±1.05)L, (78.96± 3.25)% vs (66.35±4.79)%], the difference was statistically significant (P<0.05). The total effective rate of the study group was 91.11%, which was higher than that of the control group 80.00%,the difference was statistically significant (P<0.05). Conclusion Montelukast sodium combined with budesonide is effective in the treatment of cough variant asthma, promotes the related symptoms, improves lung function, and quickly stabilizes the disease, providing a guarantee for prognosis.